SCHEMBL5452383

SCHEMBL5452383

NC(=O)c1c(NC(=O)C2CC2c2ccccc2)sc2c1CCOC2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
CFTR P13569 1/20 0.56
RAB7A P51149 1/20 0.49
PTPRC P08575 1/20 0.48
PTPN2 P17706 1/20 0.48
PTPN1 P18031 1/20 0.48
PTPRB P23467 1/20 0.48
PTPRE P23469 1/20 0.48
POLB P06746 2/20 0.47
CASP6 P55212 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ALDH1A1 P00352 5/20 0.46
MAPT P10636 1/20 0.46
RECQL P46063 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
FLT3 P36888 1/20 0.46
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8289504 0.86 NPC1 (0.63) LMNASMN1; SMN2CFTRPOLBCASP6
SCHEMBL5458883 0.86 POLB (0.63) LMNASMN1; SMN2CFTRPOLBCASP6
SCHEMBL5460380 0.83 CFTR (0.60) SMN1; SMN2CFTRPTPRCPTPN2PTPN1
SCHEMBL5466126 0.81 CFTR (0.57) SMN1; SMN2CFTRPTPRCPTPN2PTPN1
SCHEMBL5457615 0.80 CFTR (0.50) SMN1; SMN2CFTRRAB7APTPRCPTPN2
SCHEMBL5455947 0.79 MEN1 (0.65) LMNACFTRRAB7APTPRCPTPN2
SCHEMBL5450939 0.78 CFTR (0.54) SMN1; SMN2CFTRPTPRCPTPN2PTPN1
SCHEMBL5452074 0.78 CFTR (0.56) SMN1; SMN2CFTRPTPRCPTPN2PTPN1
SCHEMBL14361079 0.78 CFTR (0.56) SMN1; SMN2CFTRPTPRCPTPN2PTPN1
SCHEMBL5451008 0.78 CFTR (0.59) LMNACFTRRAB7APTPRCPTPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 LMNA 3232/4885SMN1; SMN2 2157/4885CFTR 2030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.